Actively Recruiting
Topical Insulin for Glaucoma
Led by Stanford University · Updated on 2025-11-25
52
Participants Needed
1
Research Sites
247 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
CONDITIONS
Official Title
Topical Insulin for Glaucoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Capable to provide informed consent
- Diagnosis of optic neuropathy including glaucoma, NAION, or optic disc drusen
- Only one eye per patient will be selected as the study eye, chosen by worse acuity or visual field if both eyes qualify
You will not qualify if you...
- Pregnant or breastfeeding women
- Presence of other ocular diseases causing severe vision loss such as retinopathy, maculopathy, severe uveitis, or keratopathy
- Diagnosis of glucose intolerance or type 1 or type 2 diabetes mellitus
- Inability to perform reliable visual field testing
- Unable to provide informed consent
- Unable to complete required tests and follow-ups for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Byers Eye Institute at Stanford University
Palo Alto, California, United States, 94303
Actively Recruiting
Research Team
M
Mariana Nunez, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here